Last update 01 Nov 2024

Horizon Therapeutics Ireland DAC

Subsidiary Company|
Ireland

Overview

Tags

Skin and Musculoskeletal Diseases
Other Diseases
Immune System Diseases
Monoclonal antibody
siRNA
Interferons

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases3
Neoplasms3
Endocrinology and Metabolic Disease2
Hemic and Lymphatic Diseases2
Infectious Diseases1
Nervous System Diseases1
Top 5 Drug TypeCount
Monoclonal antibody2
Interferons1
siRNA1
Top 5 TargetCount
IFNGR1(interferon gamma receptor 1)1
IGF-1R(Insulin-like growth factor I receptor)1
CD19(B-lymphocyte antigen CD19)1

Related

7
Drugs associated with Horizon Therapeutics Ireland DAC
Inebilizumab-cdon
Target
CD19
Mechanism
CD19 inhibitors [+1]
Active Org.
Horizon Therapeutics Ireland DAC [+4]
Originator Org.
Duke UniversityDuke University
Active Indication
AQP4-IgG positive Neuromyelitis optica spectrum disorder [+6]
Inactive Indication
Aggressive B-Cell Non-Hodgkin Lymphoma [+8]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date11 Jun 2020
Teprotumumab-TRBW
Target
IGF-1R
Mechanism
IGF-1R antagonists
Active Org.
Amgen Australia Pty Ltd. [+3]
Originator Org.
Genmab A/SGenmab A/S
Active Indication
Graves Ophthalmopathy [+1]
Inactive Indication
Advanced breast cancer [+10]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date21 Jan 2020
Interferon gamma-1b
Target
IFNGR1
Mechanism
IFNγR1 agonists
Active Org.
Horizon Therapeutics USA, Inc. [+4]
Originator Org.
Genentech, Inc.Genentech, Inc.
Active Indication
Osteopetrosis [+5]
Inactive Indication
Asthma [+23]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date20 Dec 1990
12
Clinical Trials associated with Horizon Therapeutics Ireland DAC
NCT06212245 / Not yet recruitingPhase 4
An Open-label Single-arm Clinical Study to Assess the Efficacy and Safety of Inebilizumab in Chinese Adult Patients With Neuromyelitis Optica Spectrum Disorders (NMOSD)
CTR20234069 / RecruitingPhase 4
在视神经髓系谱系疾病（NMOSD）成人患者中评估伊奈利珠单抗（Inebilizumab）的疗效和安全性的开放单臂临床研究
[Translation] An open-label, single-arm clinical study evaluating the efficacy and safety of Inebilizumab in adult patients with neuromyeloid spectroscopy (NMOSD)
CTRI/2023/01/048803 / Active, not recruitingPhase 2
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability ofDaxdilimab (HZN-7734) in Subjects with Systemic Lupus Erythematosus - RECAST SLE OLE
100 Clinical Results associated with Horizon Therapeutics Ireland DAC
Login to view more data
0 Patents (Medical) associated with Horizon Therapeutics Ireland DAC
Login to view more data
100 Deals associated with Horizon Therapeutics Ireland DAC
Login to view more data
100 Translational Medicine associated with Horizon Therapeutics Ireland DAC
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
1
3
Approved
Other
3
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free